Alzheimer's Drug Discovery Foundation

The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure #Alzheimers.

[Alzheimer's Drug Discovery Foundation @TheADDF]

“Our goal cannot be simply to extend lifespan; it must be to extend healthspan, with brain health at the center.”

Read The Future of Aging and Longevity: A Decade of Progress, A Decade to Act, featuring Dr. Howard Fillit and Dr. Miranda Orr: https://t.co/GbbdUqOjWF

[Ernest Scheyder @ErnestScheyder]

Two week to go until running the NYC Marathon for @TheADDF. Donate today!👇🏃🏽‍♂️

[Alzheimer's Drug Discovery Foundation @TheADDF]

On World Alzheimer’s Day, we recognize the urgency and extraordinary progress underway. The ADDF is investing in bold science and helping accelerate a future in which combination therapies and precision medicine define how we diagnose and ultimately treat Alzheimer’s.

[Alzheimer's Drug Discovery Foundation @TheADDF]

Sex hormones like estrogen have long been studied for their role in women’s health, and researchers are continuing to uncover how hormonal changes across menopause may influence brain health. @LiveScience
https://t.co/19bGSG3R7q

[Ernest Scheyder @ErnestScheyder]

Less than two months to go until the @nycmarathon, which I’m running for @TheADDF.

I would love your support:
https://t.co/MJjR6LS7oS

[Alzheimer's Drug Discovery Foundation @TheADDF]

We’re thrilled to introduce the ADDF’s new LinkedIn newsletter. Each issue will bring you exclusive insights from our scientists and leaders, along with the latest scientific advances, investment trends, and key developments shaping the field. https://t.co/M779haHFRD

[Alzheimer's Drug Discovery Foundation @TheADDF]

The ADDF’s Aaron Burstein spoke with @Inc about LM11A-31, an experimental therapy from ADDF-funded PharmatrophiX that may protect synapses and reduce harmful changes linked to both tau and amyloid in Alzheimer’s.

https://t.co/FYDHFiguK4

[Alzheimer's Drug Discovery Foundation @TheADDF]

The ADDF’s CEO, Isobel Coleman, has seen firsthand the extraordinary progress in Alzheimer’s research. She shares how the ADDF will carry that progress forward through scientific expertise, strategic investment, and collaboration. https://t.co/VCojaQSTRu

[Alzheimer's Drug Discovery Foundation @TheADDF]

The FDA clearance of @C2NDiagnostics' PrecivityAD2 blood test marks another major milestone in the rapid shift toward more accessible and scalable Alzheimer’s diagnostics, moving Alzheimer’s care closer to precision medicine.
https://t.co/nsoBdGceDd

[Alzheimer's Drug Discovery Foundation @TheADDF]

The ADDF's CEO, Isobel Coleman, shares her vision for the ADDF’s next chapter, driving greater impact across Alzheimer’s research while building on its scientific legacy and catalyzing progress in drug development, biomarkers, and prevention.

https://t.co/VCojaQSTRu

[Inc. @Inc]

Researchers say the oral drug LM11A-31 slowed the decline of brain-network function in a small trial, pointing to a potential broader strategy for treating Alzheimer’s. https://t.co/vGUYpAta2s

[Alzheimer's Drug Discovery Foundation @TheADDF]

Tau research is gaining momentum as the field looks beyond amyloid. In @AARP, the ADDF's Interim Chief Science Officer Laura Nisenbaum explains why tau is closely tied to cognitive decline and why it remains an important target in Alzheimer’s. https://t.co/zz0CYRV3nD

[Healio Psychiatry @HealioPsych]

Patients with early #Alzheimers disease experienced slower cognitive decline and greater reductions in #tau with #diranersen compared with placebo, researchers from @biogen said at #AAIC26. Also, @TheADDF comments.

@alzassociation

https://t.co/h84A36fIaQ

[Alzheimer's Drug Discovery Foundation @TheADDF]

For 25 years, the ADDF has supported the work of Dr. Frank Longo, including an early investment in PharmatrophiX. That long-term support is reflected in the continued progress of LM11A-31, which Dr. Longo recently discussed on @CNBC's Squawk Box.

https://t.co/y0cjHvixSg

[Healio Psychiatry @HealioPsych]

“Subcutaneous approval is an important step toward the kind of scalable care model #Alzheimers will need as the field moves from single-drug treatment toward combination therapies,” said Dr. Laura Nisenbaum of @TheADDF.

#lecanemab #leqembi

https://t.co/Pl9YtXXp9H

[Alzheimer's Drug Discovery Foundation @TheADDF]

New phase 2 data presented by @Biogen today at #AAIC2026 show diranersen (#BIIB080) is the first tau-targeting drug to demonstrate a robust biomarker effect and clinical signal.

Read more: https://t.co/sm1VMoyIW0

[Alzheimer's Drug Discovery Foundation @TheADDF]

The ADDF’s Diagnostics Accelerator and @MichaelJFoxOrg are joining forces to accelerate the development of scalable, minimally invasive biomarkers for co-pathologies found across Alzheimer’s and Parkinson’s.
Learn more: https://t.co/C1a4B4rOop

[Healio Neurology @healioneurology]

“#Alzheimer’s is not driven by a single mechanism. It involves amyloid, tau, and novel pathways like #inflammation, vascular health and metabolism,” Dr. Laura Nisenbaum of @TheADDF said about what she expects to see at #AAIC26.

@alzassociation

https://t.co/DLFJAAWFIT

[Alzheimer's Drug Discovery Foundation @TheADDF]

New in Solving Alzheimer's: the ADDF's Laura Nisenbaum explores how Alzheimer's diagnosis is evolving. From FDA-cleared blood tests to AI-powered tools, these innovations are making detection more accessible, scalable, and precise.

https://t.co/DuFQ02Z6hK

[Ernest Scheyder @ErnestScheyder]

Friends, I'm running the @NYCMarathon this fall for @TheADDF for the 12th time. I'd love your support as I run to help find better treatment and a cure for Alzheimer's! 🏃‍♂️🏃‍♂️🏃‍♂️ #TeamADDF
More info here: https://t.co/MJjR6LRzzk